Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aptose Biosciences (APTO)
NASDAQ:APTO
RESEARCH TOOLSreports
Holding APTO?
Track your performance easily
APTO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.13 - $2.68
Previous Close$0.28
Volume306.25M
Average Volume (3M)6.04M
Market Cap
$17.43M
Enterprise Value$10.19M
Total Cash (Recent Filing)$7.96M
Total Debt (Recent Filing)$721.00K
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Mar 25, 2025EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.05
Shares Outstanding18,109,393
10 Day Avg. Volume5,562,624
30 Day Avg. Volume6,041,327
Standard Deviation0.26
R-Squared0.04
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)-0.56
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.29
Forecast
1Y Price Target
$2.00Price Target Upside616.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Aptose Biosciences News
PremiumCompany Announcements
Aptose Biosciences Granted Nasdaq Compliance ExtensionPremiumCompany Announcements
Aptose Biosciences Publishes Promising Preclinical Data on Tuspetinib
PremiumCompany Announcements
Aptose Biosciences Advances TUS as AML TherapyBulls Say, Bears Say
Bulls Say
Clinical AdvancementsTuspetinib is shaping up to be a welcome addition to first-line advanced AML, offering a new approach to treat patients with oncogenic mutations associated with poor prognosis.
Collaborations And PartnershipsAptose collaborates with the National Cancer Institute to advance tuspetinib combination therapies for treating acute myeloid leukemia and myelodysplastic syndrome, leveraging its promising safety profile and observed clinical activity.
Financial SupportAptose secured a $10 million loan from Hanmi Pharmaceutical, which could provide further financial support for the clinical development of tuspetinib and potentially accelerate its progress in ongoing trials.
Bears Say
Capital RaisingAptose is actively raising capital, which should help the company's path forward while also being significantly dilutive in order to maintain operations.
Drug ToxicityVEN/AZA is associated with high incidence of toxicity and frequently requires dose adjustments to remain tolerable.
Treatment EfficacyMany contemporary first-line chemotherapeutic regimens have low response rates and survival benefits leave room for improvement.
---
Ownership Overview
2.36% Insiders
<0.01% Mutual Funds
5.06% Other Institutional Investors
92.58% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
APTO FAQ
What was Aptose Biosciences’s price range in the past 12 months?
Aptose Biosciences lowest stock price was $0.13 and its highest was $2.68 in the past 12 months.
What is Aptose Biosciences’s market cap?
Currently, no data Available
When is Aptose Biosciences’s upcoming earnings report date?
Aptose Biosciences’s upcoming earnings report date is Mar 25, 2025 which is in 93 days.
How were Aptose Biosciences’s earnings last quarter?
Aptose Biosciences released its earnings results on Nov 08, 2024. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.64 by $0.27.
Is Aptose Biosciences overvalued?
According to Wall Street analysts Aptose Biosciences’s price is currently Undervalued.
Does Aptose Biosciences pay dividends?
Aptose Biosciences does not currently pay dividends.
What is Aptose Biosciences’s EPS estimate?
Aptose Biosciences’s EPS estimate is -$0.35.
How many shares outstanding does Aptose Biosciences have?
Aptose Biosciences has 59,521,183 shares outstanding.
What happened to Aptose Biosciences’s price movement after its last earnings report?
Aptose Biosciences reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.64. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aptose Biosciences?
Among the largest hedge funds holding Aptose Biosciences’s share is Carlson Capital LP. It holds Aptose Biosciences’s shares valued at N/A.
---
Aptose Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (616.85% Upside)
$2.00 (616.85% Upside)
Hedge Fund Trend
Decreased
By 96.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 3.4%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-47.65%
Trailing 12-Months
Company Description
Aptose Biosciences
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
---
APTO Earnings Call
Q1 2024
0:00 / 0:00
---
APTO Stock 12 Month Forecast
Average Price Target
$2.00
▲(616.85% Upside)
Technical Analysis
Best Analysts Covering APTO
1 Year
1 Year Success Rate
1/18 ratings generated profit
1 Year Average Return
-60.54%
reiterated a buy rating 7 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 5.56% of your transactions generating a profit, with an average return of -60.54% per trade.
---